Bacteria and bacterial toxins as therapeutic agents for solid tumors

Current Cancer Drug Targets

Volumn 4, Issue 8, 2004, Pages 689-702

  Michl, P ^a   Gress, T M ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Bacteria; Bifidobacterium; Cancer; Clostridium; Diphtheria; Pseudomonas; Salmonella; Toxin

Indexed keywords

ANTIBODY AGAINST HEPATOCELLULAR ANTIGEN P 148 DIPHTHERIA TOXIN FRAGMENT A FUSION PROTEIN; ANTINEOPLASTIC AGENT; ASIALOFETUIN DIPTHERIA TOXIN FRAGMENT A FUSION PROTEIN; BACTERIAL TOXIN; CLOSTRIDIUM PERFRINGENS ENTEROTOXIN; CLOSTRIDIUM TOXIN; DIPHTHERIA TOXIN; DIPHTHERIA TOXIN ALPHA INTERMEDIN FUSION PROTEIN; DIPHTHERIA TOXIN EPIDERMAL GROWTH FACTOR FUSION PROTEIN; DIPHTHERIA TOXIN NEUROTROPHIN 4 FUSION PROTEIN; DIPHTHERIA TOXIN TETANUS TOXIN C TERMINAL FRAGMENT FUSION PROTEIN; DIPHTHERIA TOXIN VASCULOTROPIN FUSION PROTEIN; HYBRID PROTEIN; INTERLEUKIN 13 PSEUDOMONAS EXOTOXIN A FUSION PROTEIN; INTERLEUKIN 4 [38-37] PSEUDOMONAS EXOTOXIN A FUSION PROTEIN; LMB 1 PROTEIN; MONOCLONAL ANTIBODY 44D5MOCB ETA CONJUGATE; MONOCLONAL ANTIBODY 8H9 FV FRAGMENT PSEUDOMONAS EXOTOXIN A CONJUGATE; MONOCLONAL ANTIBODY 9.2.27 PSEUDOMONAS EXOTOXIN A CONJUGATE; MONOCLONAL ANTIBODY E23 PSEUDOMONAS EXOTOXIN A CONJUGATE; MONOCLONAL ANTIBODY SSI(DSFV) PSEUDOMONAS EXOTOXIN A CONJUGATE; MONOCLONAL ANTIBODY TP 3(DSFV) PSEUDOMONAS EXOTOXIN A CONJUGATE; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN A; SINGLE CHAIN FV FRAGMENT PSEUDOMONAS EXOTOXIN A FUSION PROTEIN; SINGLE CHAIN FV FRAGMENT(FRP5) ETA FUSION PROTEIN; TRANSFERRIN DIPHTHERIA TOXIN CRM 107 CONJUGATE; TRANSFERRIN RECEPTOR DIPHTHERIA TOXIN CRM107 CONJUGATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE DIPHTHERIA TOXIN FUSION PROTEIN;

ASTHENIA; BIFIDOBACTERIUM; CANCER RECURRENCE; CELL SURFACE; CLINICAL TRIAL; CLOSTRIDIUM; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; FEVER; GENE OVEREXPRESSION; HUMAN; LIVER TOXICITY; METASTASIS; NAUSEA; REVIEW; SALMONELLA; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; BACTERIA; BACTERIAL PROTEINS; BACTERIAL TOXINS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS;

EID: 10944273968     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009043332727     Document Type: Review

References (116)

1. Kreitman, R. J. Recombinant toxins for the treatment of cancer. Curr. Opin. Mol. Ther. 2003, 5, 44-51.
2. Kreitman, R. J. Toxin-labeled monoclonal antibodies. Curr. Pharm. Biotechnol. 2001, 2, 313-325.
3. Holmes, R. K. Biology and molecular epidemiology of diphtheria toxin and the tox gene. J. Infect. Dis. 2000, 181(Suppl. 1), S156-S167.
4. Rolf, J. M.; Gaudin, H. M.; Eidels, L. Localization of the diphtheria toxin receptor-binding domain to the carboxyl-terminal Mr approximately 6000 region of the toxin. J. Biol. Chem. 1990, 265, 7331-7337.
5. Louie, G. V.; Yang, W.; Bowman, M. E.; Choe, S. Crystal structure of the complex of diphtheria toxin with an extracellular fragment of its receptor. Mol. Cell 1997, 1, 67-78.
6. Frankel, A. E.; Rossi, P.; Kuzel, T. M.; Foss, F. Diphtheria fusion protein therapy of chemoresistant malignancies. Curr. Cancer Drug Targets 2002, 2, 19-36.
7. Lanzrein, M.; Sand, O.; Olsnes, S. GP1-anchored diphtheria toxin receptor allows membrane translocation of the toxin without detectable ion channel activity. EMBO J. 1996, 15, 725-734.
8. Falnes, P. O.; Ariansen, S.; Sandvig, K.; Olsnes, S. Requirement for prolonged action in the cytosol for optimal protein synthesis inhibition by diphtheria toxin. J. Biol. Chem. 2000, 275, 4363-4368.
9. Greenfield, L.; Johnson, V. G.; Youle, R. J. Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. Science 1987, 238, 536-539.
10. Rustamzadeh, E.; Li, C.; Doumbia, S.; Hall, W. A.; Vallera, D. A. Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme. J. Neurooncol. 2003, 65, 63-75.
11. Johnson, V. G.; Wrobel, C.; Wilson, D.; Zovickian, J.; Greenfield, L.; Oldfield, E. H.; Youle, R. Improved tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia. J. Neurosurg. 1989, 70, 240-248.
12. Liu, T. F.; Cohen, K. A.; Ramage, J. G.; Willingham, M. C.; Thorburn, A. M.; Frankel, A. E. A diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cells. Cancer Res. 2003, 63, 1834-1837.
13. Mishra, G.; Liu, T. F.; Frankel, A. E. Recombinant toxin DAB389EGF is cytotoxic to human pancreatic cancer cells. Expert. Opin. Biol. Ther. 2003, 3, 1173-1180.
14. Landgraf, R.; Pegram, M.; Slamon, D. J.; Eisenberg, D. Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin beta1. Biochemistry 1998, 37, 3220-3228.
15. Zheng, J. Y.; Chen, D.; Chan, J.; Yu, D.; Ko, E.; Pang, S. Regression of prostate cancer xenografts by a lentiviral vector specifically expressing diphtheria toxin A. Cancer Gene Ther. 2003, 10, 764-770.
16. Ayesh, B.; Matouk, I.; Ghana, P.; Sughayer, M. A.; Birman, T.; Ayesh, S.; Schneider, T.; de Groot, N.; Hochberg, A. Inhibition of tumor growth by DT-A expressed under the control of IGF2 P3 and P4 promoter sequences. Mol. Ther. 2003, 7, 535-541.
17. Hotz, H. G.; Gill, P. S.; Masood, R.; Hotz, B.; Buhr, H. J.; Foitzik, T.; Hines, O. J.; Reber, H. A. Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer. J. Gastrointest. Surg. 2002, 6, 159-166.
18. Masood, R.; Kundra, A.; Zhu, S.; Xia, G.; Scalia, P.; Smith, D. L.; Gill, P. S. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int. J. Cancer 2003, 104, 603-610.
19. Takahashi, T.; Umata, T.; Mekada, E. Extension of juxtamembrane domain of diphtheria toxin receptor arrests translocation of diphtheria toxin fragment A into cytosol. Biochem. Biophys. Res. Commun. 2001, 281, 690-696.
20. Laske, D. W.; Youle, R. J.; Oldfield, E. H. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat. Med. 1997, 3, 1362-1368.
21. Hagihara, N.; Walbridge, S.; Olson, A. W.; Oldfield, E. H.; Youle, R. J. Vascular protection by chloroquine during brain tumor therapy with Tf-CRM107. Cancer Res. 2000, 60, 230-234.
22. Herschman, H. R.; Simpson, D. L.; Cawley, D. B. Toxic ligand conjugates as tools in the study of receptor-ligand interactions. J. Cell Biochem. 1982, 20, 163-176.
23. Shaw, J. P.; Akiyoshi, D. E.; Arrigo, D. A.; Rhoad, A. E.; Sullivan, B.; Thomas, J.; Genbauffe, F. S.; Bacha, P.; Nichols, J. C. Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins. J. Biol. Chem. 1991, 266, 21118-21124.
24. Pastan, I. Targeted therapy of cancer with recombinant immunotoxins. Biochim. Biophys. Acta 1997, 1333, C1-C6.
25. Hwang, J.; Fitzgerald, D. J.; Adhya, S.; Pastan, I. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell 1987, 48, 129-136.
26. Allured, V. S.; Collier, R. J.; Carroll, S. F.; McKay, D. B. Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. Proc. Natl. Acad. Sci. USA 1986, 83, 1320-1324.
27. Li, M.; Dyda, F.; Benhar, I.; Pastan, I.; Davies, D. R. Crystal structure of the catalytic domain of Pseudomonas exotoxin A complexed with a nicotinamide adenine dinucleotide analog: implications for the activation process and for ADP ribosylation. Proc. Natl. Acad. Sci. USA 1996, 93, 6902-6906.
28. Hessler, J. L.; Kreitman, R. J. An early step in Pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptor. Biochemistry 1997, 36, 14577-14582.
29. Kounnas, M. Z.; Morris, R. E.; Thompson, M. R.; Fitzgerald, D. J.; Strickland, D. K.; Saelinger, C. B. The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. J. Biol. Chem. 1992, 267, 12420-12423.
30. Ogata, M.; Fryling, C. M.; Pastan, I.; Fitzgerald, D. J. Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol. J. Biol. Chem. 1992, 267, 25396-25401.
31. McKee, M. L.; Fitzgerald, D. J. Reduction of furin-nicked Pseudomonas exotoxin A: an unfolding story. Biochemistry 1999, 38, 16507-16513.
32. Kreitman, R. J.; Pastan, I. Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem. J. 1995, 307, 29-37.
33. Theuer, C.; Kasturi, S.; Pastan, I. Domain II of Pseudomonas exotoxin A arrests the transfer of translocating nascent chains into mammalian microsomes. Biochemistry 1994, 33, 5894-5900.
34. Brinkmann, U.; Brinkmann, E.; Gallo, M.; Pastan, I. Cloning and characterization of a cellular apoptosis susceptibility gene, the human homologue to the yeast chromosome segregation gene CSE1. Proc. Natl. Acad. Sci. USA 1995, 92, 10427-10431.
35. Fan, D.; Yano, S.; Shinohara, H.; Solorzano, C.; Van Arsdall, M.; Bucana, C. D.; Pathak, S.; Kruzel, E.; Herbst, R. S.; Onn, A.; Roach, J. S.; Onda, M.; Wang, Q. C.; Pastan, I.; Fidler, I. J. Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin. Mol. Cancer Ther. 2002, 1, 595-600.
36. Pastan, I.; Chaudhary, V.; Fitzgerald, D. J. Recombinant toxins as novel therapeutic agents. Annu. Rev. Biochem. 1992, 61, 331-354.
37. Pastan, I.; Lovelace, E. T.; Gallo, M. G.; Rutherford, A. V.; Magnani, J. L.; Willingham, M. C. Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas. Cancer Res. 1991, 51, 3781-3787.
38. Pai, L. H.; Wittes, R.; Setser, A.; Willingham, M. C.; Pastan, I. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat. Med. 1996, 2, 350-353.
39. Reiter, Y.; Brinkmann, U.; Jung, S. H.; Lee, B.; Kasprzyk, P. G.; King, C. R.; Pastan, I. Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. J. Biol. Chem. 1994, 209, 18327-18331.
40. Onda, M.; Wang, Q. C.; Guo, H. F.; Cheung, N. K.; Pastan, I. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma. Cancer Res. 2004, 64, 1419-1424.
41. Posey, J. A.; Khazaeli, M. B.; Bookman, M. A.; Nowrouzi, A.; Grizzle, W. E.; Thornton, J.; Carey, D. E.; Lorenz, J. M.; Sing, A. P.; Siegall, C. B.; LoBuglio, A. F.; Saleh, M. N. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Clin. Cancer Res. 2002, 8, 3092-3099.
42. Leland, P.; Taguchi, J.; Husain, S. R.; Kreitman, R. J.; Pastan, I.; Puri, R. K. Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo. Mol. Med. 2000, 6, 165-178.
43. Joshi, B. H.; Leland, P.; Silber, J.; Kreitman, R. J.; Pastan, I.; Berger, M.; Puri, R. K. IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein. Br. J. Cancer 2002, 86, 285-291.
44. Kawakami, K.; Kawakami, M.; Joshi, B. H.; Puri, R. K. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Cancer Res. 2001, 61, 6194-6200.
45. Kawakami, K.; Leland, P.; Puri, R. K. Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells. Cancer Res. 2000, 60, 2981-2987.
46. Kawakami, K.; Kawakami, M.; Husain, S. R.; Puri, R. K. Targeting interleukin-4 receptors for effective pancreatic cancer therapy. Cancer Res. 2002, 62, 3575-3580.
47. Rand, R. W.; Kreitman, R. J.; Patronas, N.; Varricchio, F.; Pastan, I.; Puri, R. K. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin. Cancer Res. 2000, 6, 2157-2165.
48. Weber, F. W.; Floeth, F.; Asher, A.; Bucholz, R.; Berger, M.; Prados, M.; Chang, S.; Bruce, J.; Hall, W.; Rainov, N. G.; Westphal, M.; Warnick, R. E.; Rand, R. W.; Rommell, F.; Pan, H.; Hingorani, V. N.; Puri, R. K. Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir. Suppl. 2003, 88, 93-103.
49. Kawakami, M.; Kawakami, K.; Puri, R. K. Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts. Mol. Cancer Ther. 2002, 1, 999-1007.
50. Liu, T. F.; Willingham, M. C.; Tatter, S. B.; Cohen, K. A.; Lowe, A. C.; Thorburn, A.; Frankel, A. E. Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells. Bioconjug. Chem. 2003, 14, 1107-1114.
51. Husain, S. R.; Puri, R. K. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J. Neurooncol. 2003, 65, 37-48.
52. Kunwar, S. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase I studies. Acta Neurochir. Suppl. 2003, 88, 105-111.
53. Wang, L.; Liu, B.; Schmidt, M.; Lu, Y.; Wels, W.; Fan, Z. Antitumor effect of an HER2-specific antibody-toxin fusion protein on human prostate cancer cells. Prostate 2001, 47, 21-28.
54. Bera, T. K.; Viner, J.; Brinkmann, E.; Pastan, I. Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2. Cancer Res. 1999, 59, 4018-4022.
55. Bruell, D.; Stocker, M.; Huhn, M.; Redding, N.; Kupper, M.; Schumacher, P.; Paetz, A.; Bruns, C. J.; Haisma, H. J.; Fischer, R.; Finnern, R.; Barth, S. The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line. Int. J. Oncol. 2003, 23, 1179-1186.
56. Beers, R.; Chowdhury, P.; Bigner, D.; Pastan, I. Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display. Clin. Cancer Res. 2000, 6, 2835-2843.
57. Sampson, J. H.; Akabani, G.; Archer, G. E.; Bigner, D. D.; Berger, M. S.; Friedman, A. H.; Friedman, H. S.; Herndon, J. E.; Kunwar, S.; Marcus, S.; McLendon, R. E.; Paolino, A.; Penne, K.; Provenzale, J.; Quinn, J.; Reardon, D. A.; Rich, J.; Stenzel, T.; Tourt-Uhlig, S.; Wikstrand, C.; Wong, T.; Williams, R.; Yuan, F.; Zalutsky, M. R.; Pastan, I. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J. Neurooncol. 2003, 65, 27-35.
58. Johnson, E. A. Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins. Annu. Rev. Microbiol. 1999, 53, 551-575.
59. Kokai-Kun, J. F.; McClane, B. A. Deletion analysis of the Clostridium perfringens enterotoxin. Infect. Immun. 1997, 65, 1014-1022.
60. McClane, B. A. Clostridium perfringens enterotoxin acts by producing small molecule permeability alterations in plasma membranes. Toxicology 1994, 87, 43-67.
61. Sarker, M. R.; Carman, R. J.; McClane, B. A. Inactivation of the gene (cpe) encoding Clostridium perfringens enterotoxin eliminates the ability of two cpe-positive C. perfringens type A human gastrointestinal disease isolates to affect rabbit ileal loops. Mol. Microbiol. 1999, 33, 946-958.
62. Wieckowski, E. U.; Wnek, A. P.; McClane, B. A. Evidence that an approximately 50-kDa mammalian plasma membrane protein with receptor-like properties mediates the amphiphilicity of specifically bound Clostridium perfringens enterotoxin. J. Biol. Chem. 1994, 269, 10838-10848.
63. McClane, B. A.; McDonel, J. L. The effects of Clostridium perfringens enterotoxin on morphology, viability, and macromolecular synthesis in Vero cells. J. Cell Physiol. 1979, 99, 191-200.
64. Kokai-Kun, J. F.; McClane, B. A. Determination of functional regions of Clostridium perfringens enterotoxin through deletion analysis. Clin. Infect. Dis. 1997, 25(Suppl 2), S165-S167.
65. Kokai-Kun, J. F.; Benton, K.; Wieckowski, E. U.; McClane, B. A. Identification of a Clostridium perfringens enterotoxin region required for large complex formation and cytotoxicity by random mutagenesis. Infect. Immun. 1999, 67, 5634-5641.
66. Katahira, J.; Inoue, N.; Horiguchi, Y.; Matsuda, M.; Sugimoto, N. Molecular cloning and functional characterization of the receptor for Clostridium perfringens enterotoxin. J. Cell Biol. 1997, 136, 1239-1247.
67. Fujita, K.; Katahira, J.; Horiguchi, Y.; Sonoda, N.; Furuse, M.; Tsukita, S. Clostridium perfringens enterotoxin binds to the second extracellular loop of claudin-3, a tight junction integral membrane protein. FEBS Lett. 2000, 476, 258-261.
68. Chen, Y.; Lu, Q.; Schneeberger, E. E.; Goodenough, D. A. Restoration of tight junction structure and barrier function by down-regulation of the mitogen-activated protein kinase pathway in ras-transformed Madin-Darby canine kidney cells. Mol. Biol. Cell 2000, 11, 849-862.
69. Heiskala, M.; Peterson, P. A.; Yang, Y. The roles of claudin superfamily proteins in paracellular transport. Traffic 2001, 2, 93-98.
70. Rahner, C.; Mitic, L. L.; Anderson, J. M. Heterogeneity in expression and subcellular localization of claudins 2, 3, 4, and 5 in the rat liver, pancreas, and gut. Gastroenrerology 2001, 120, 411-422.
71. Gress, T. M.; Muller-Pillasch, F.; Geng, M.; Zimmerhackl, F.; Zehetner, G.; Friess, H.; Buchler, M.; Adler, G.; Lehrach, H. A pancreatic cancer-specific expression profile. Oncogene 1996, 13, 1819-1830.
72. Michl, P.; Buchholz, M.; Rolke, M.; Kunsch, S.; Lohr, M.; McClane, B.; Tsukita, S.; Leder, G.; Adler, G.; Gress, T. M. Claudin-4: a new target lor pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology 2001, 121, 678-684.
73. Hough, C. D.; Sherman-Baust, C. A.; Pizer, E. S.; Montz, F. J.; Im, D. D.; Rosenshein, N. B.; Cho, K. R.; Riggins, G. J.; Morin, P. J. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 2000, 60, 6281-6287.
74. Kominsky, S. L.; Vali, M.; Korz, D.; Gabig, T. G.; Weitzman, S. A.; Argani, P.; Sukumar, S. Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. Am. J. Pathol 2004, 164, 1627-1633.
75. Muller, P.; Jesnowski, R.; Karle, P.; Renz, R.; Saller, R.; Stein, H.; Puschel, K.; von Rombs, K.; Nizze, H.; Liebe, S.; Wagner, T.; Gunzburg, W. H.; Salmons, B.; Lohr, M. Injection of encapsulated cells producing an ifosfamide-activating cytochrome P450 for targeted chemotherapy to pancreatic tumors. Ann. NY Acad. Sci. 1999, 880, 337-351.
76. Hanna, P. C.; Wnek, A. P.; McClane, B. A. Molecular cloning of the 3′ half of the Clostridium perfringens enterotoxin gene and demonstration that this region encodes receptor-binding activity. J. Bacteriol. 1989, 171, 6815-6820.
77. Sonoda, N.; Furuse, M.; Sasaki, H.; Yonemura, S.; Katahira, J.; Horiguchi, Y.; Tsukita, S. Clostridium perfringens enterotoxin fragment removes specific claudins from tight junction strands: Evidence for direct involvement of claudins in tight junction barrier. J. Cell Biol. 1999, 147, 195-204.
78. Dang, L. H.; Bettegowda, C.; Huso, D. L.; Kinzler, K. W.; Vogelstein, B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc. Natl. Acad. Sci. USA 2001, 98, 15155-15160.
79. Minton, N. P. Clostridia in cancer therapy. Nat. Rev. Microbiol. 2003, 1, 237-242.
80. Malmgren, R. A.; Flanigan, C. C. Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration. Cancer Res. 1955, 15, 473-478.
81. Pawelek, J. M.; Low, K. B.; Bermudes, D. Bacteria as tumour-targeting vectors. Lancet Oncol. 2003, 4, 548-556.
82. Moese, J. R.; Moese, G. Oncolysis by clostridia. I. Activity of Clostridium butyricum (M-55) and other nonpathogenic clostridia against the Ehrlich carcinoma. Cancer Res. 1964, 24, 212-216.
83. Bettegowda, C.; Dang, L. H.; Abrams, R.; Huso, D. L.; Dillehay, L.; Cheong, I.; Agrawal, N.; Borzillary, S.; McCaffery, J. M.; Watson, E. L.; Lin, K. S.; Bunz, F.; Baidoo, K.; Pomper, M. G.; Kinzler, K. W.; Vogelstein, B.; Zhou, S. Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria. Proc. Natl. Acad. Sci. USA 2003, 100, 15083-15088.
84. Harrison, L. B.; Chadha, M.; Hill, R. J.; Hu, K.; Shasha, D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 2002, 7, 492-508.
85. Theys, J.; Nuyts, S.; Landuyt, W.; Van Mellaert, L.; Dillen, C.; Bohringer, M.; Durre, P.; Lambin, P.; Anne, J. Stable Escherichia coli-Clostridium acetobutylicum shuttle vector for secretion of murine tumor necrosis factor alpha. Appl. Environ. Microbiol. 1999, 65, 4295-4300.
86. Theys, J.; Landuyt, W.; Nuyts, S.; Van Mellaert, L.; van Oosterom, A.; Lambin, P.; Anne, J. Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum. Cancer Gene Ther. 2001, 8, 294-297.
87. Liu, S. C.; Minton, N. P.; Giaccia, A. J.; Brown, J. M. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther. 2002, 9, 291-296.
88. Nuyts, S.; Van Mellaert, L.; Theys, J.; Landuyt, W.; Lambin, P.; Anne, J. The use of radiation-induced bacterial promoters in anaerobic conditions: a means to control gene expression in clostridium-mediated therapy for cancer. Radiat. Res. 2001, 155, 716-723.
89. Nuyts, S.; Theys, J.; Landuyt, W.; Van Mellaert, L.; Lambin, P.; Anne, J. Increasing specificity of anti-tumor therapy: cytotoxic protein delivery by non-pathogenic clostridia under regulation of radio-induced promoters. Anticancer Res. 2001, 21, 857-861.
90. Nuyts, S.; Van Mellaert, L.; Barbe, S.; Lammertyn, E.; Theys, J.; Landuyt, W.; Bosmans, E.; Lambin, P.; Anne, J. Insertion or deletion of the Cheo box modifies radiation inducibility of Clostridium promoters. Appl. Environ. Microbiol. 2001, 67, 4464-4470.
91. Theys, J.; Landuyt, W.; Nuyts, S.; Van Mellaert, L.; Bosmans, E.; Rijnders, A.; Van Den, B. W.; van Oosterom, A.; Anne, J.; Lambin, P. Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas. FEMS Immunol. Med. Microbiol. 2001, 30, 37-41.
92. Zheng, L. M.; Luo, X.; Feng, M.; Li, Z.; Le, T.; Ittensohn, M.; Trailsmith, M.; Bermudes, D.; Lin, S. L.; King, I. C. Tumor amplified protein expression therapy: Salmonella as a tumor-selective protein delivery vector. Oncol. Res. 2000, 12, 127-135.
93. Toso, J. F.; Gill, V. J.; Hwu, P.; Marincola, F. M.; Restifo, N. P.; Schwartzentruber, D. J.; Sherry, R. M.; Topalian, S. L.; Yang, J. C.; Stock, F.; Freezer, L. J.; Morton, K. E.; Seipp, C.; Haworth, L.; Mavroukakis, S.; White, D.; MacDonald, S.; Mao, J.; Sznol, M.; Rosenberg, S. A. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J. Clin. Oncol. 2002, 20, 142-152.
94. Pawelek, J. M.; Low, K. B.; Bermudes, D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. 1997, 57, 4537-4544.
95. Soto, L. J., III; Sorenson, B. S.; Kim, A. S.; Feltis, B. A.; Leonard, A. S.; Saltzman, D. A. Attenuated Salmonella typhimurium prevents the establishment of unresectable hepatic metastases and improves survival in a murine model. J. Pediatr. Surg. 2003, 38, 1075-1079.
96. Low, K. B.; Ittensohn, M.; Le, T.; Platt, J.; Sodi, S.; Amoss, M.; Ash, O.; Carmichael, E.; Chakraborty, A.; Fischer, J.; Lin, S. L.; Luo, X.; Miller, S. I.; Zheng, L.; King, I.; Pawelek, J. M.; Bermudes, D. Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat. Biotechnol. 1999, 17, 37-41.
97. King, I.; Bermudes, D.; Lin, S.; Belcourt, M.; Pike, J.; Troy, K.; Le, T.; Ittensohn, M.; Mao, J.; Lang, W.; Runyan, J. D.; Luo, X.; Li, Z.; Zheng, L. M. Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent. Hum. Gene Ther. 2002, 13, 1225-1233.
98. Nemunaitis, J.; Cunningham, C.; Senzer, N.; Kuhn, J.; Gramm, J.; Litz, C.; Cavagnolo, R.; Cahill, A.; Clairmont, C.; Sznol, M. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther. 2003, 10, 737-744.
99. Yazawa, K.; Fujimori, M.; Amano, J.; Kano, Y.; Taniguchi, S. Bifidobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors. Cancer Gene Ther. 2000, 7, 269-274.
100. Nakamura, T.; Sasaki, T.; Fujimori, M.; Yazawa, K.; Kano, Y.; Amano, J.; Taniguchi, S. Cloned cytosine deaminase gene expression of Bifidobacterium longum and application to enzyme/pro-drug therapy of hypoxic solid tumors. Biosci. Biotechnol. Biochem. 2002, 66, 2362-2366.
101. Li, X.; Fu, G. F.; Fan, Y. R.; Liu, W. H.; Liu, X. J.; Wang, J. J.; Xu, G. X. Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther. 2003, 10, 105-111.
102. Cawley, D. B.; Simpson, D. L.; Herschman, H. R. Asialoglycoprotein receptor mediates the toxic effects of an asialofetuin-diphtheria toxin fragment A conjugate on cultured rat hepatocytes. Proc. Natl. Acad. Sci. USA 1981, 78, 3383-3387.
103. Bernhard, M. I.; Foon, K. A.; Oeltmann, T. N.; Key, M. E.; Hwang, K. M.; Clarke, G. C.; Christensenl W. L.; Hoyer, L. C.; Hanna, M. G. Jr.; Oldham, R. K. Guinea pig line 10 hepatocarcinoma model: characterization of monoclonal antibody and in vivo effect of unconjugated antibody and antibody conjugated to diphtheria toxin A chain. Cancer Res. 1983, 43, 4420-4428.
104. Wen, Z. L.; Tao, X.; Lakkis, F.; Kiyokawa, T.; Murphy, J. R. Diphtheria toxin-related alpha-melanocyte-stimulating hormone fusion toxin. Internal in-frame deletion from Thr387 to His485 results in the formation of a highly potent fusion toxin which is resistant to proteolytic degradation. J. Biol. Chem. 1991, 266, 12289-12293.
105. Murphy, J. R.; Bishai, W.; Borowski, M.; Miyanohara, A.; Boyd, J.; Nagle, S. Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related alpha-melanocyte-stimulating hormone fusion protein. Proc. Natl. Acad. Sci. USA 1986, 83, 8258-8262.
106. Francis, J. W.; Brown, R. H. Jr.; Figueiredo, D.; Remington, M. P.; Castillo, O.; Schwarzschild, M. A.; Fishman, P. S.; Murphy, J. R.; vanderSpek, J. C. Enhancement of diphtheria toxin potency by replacement of the receptor binding domain with tetanus toxin C-fragment: a potential vector for delivering heterologous proteins to neurons. J. Neurochem. 2000, 74, 2528-2536.
107. vanderSpek, J. C.; Sutherland, J. A.; Zeng, H.; Battey, J. F.; Jensen, R. T.; Murphy, J. R. Inhibition of protein synthesis in small cell lung cancer cells induced by the diphtheria toxin-related fusion protein DAB389 GRP. Cancer Res. 1997, 57, 290-294.
108. Negro, A.; Skaper, S. D. Synthesis and cytotoxic profile of a diphtheria toxin- neurotrophin-4 chimera. J. Neurochem. 1997, 68, 554-563.
109. Hassan, R.; Lerner, M. R.; Benbrook, D.; Lightfoot, S. A.; Brackett, D. J.; Wang, Q. C.; Pastan, I. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clin. Cancer Res. 2002, 8, 3520-3526.
110. Di Paolo, C.; Willuda, J.; Kubetzko, S.; Lauffer, I.; Tschudi, D.; Waibel, R.; Pluckthun, A.; Stahel, R. A.; Zangemeister-Wittke, U. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin. Cancer Res. 2003, 9, 2837-2848.
111. Niv, R.; Assaraf, Y. G.; Segal, D.; Pirak, E.; Reiter, Y. Targeting multidrug resistant tumor cells with a recombinant single-chain FV fragment directed to P-glycoprotein. Int. J. Cancer 2001, 94, 864-872.
112. Onda, M.; Olafsen, T.; Tsutsumi, Y.; Bruland OS, O. S.; Pastan, I. Cytotoxicity of Antiosteosarcoma Recombinant Immunotoxins Composed of TP-3 Fv Fragments and a Truncated Pseudomonas Exotoxin A. J. Immunother. 2001, 24, 144-150.
113. Hjortland, G. O.; Garman-Vik, S. S.; Juell, S.; Olsen, O. E.; Hirschberg, H.; Fodstad, O.; Engebraaten, O. Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme. J. Neurosurg. 2004, 100, 320-327.
114. Strome, S. E.; Kawakami, K.; Alejandro, D.; Voss, S.; Kasperbauer, J. L.; Salomao, D.; Chen, L.; Maki, R. A.; Puri, R. K. Interleukin 4 receptor-directed cytotoxin therapy for human head and neck squamous cell carcinoma in animal models. Clin. Cancer Res. 2002, 8, 281-286.
115. Schmidt, M.; McWatters, A.; White, R. A.; Groner, B.; Wels, W.; Fan, Z.; Bast, R. C. Jr. Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2. Gynecol. Oncol. 2001, 80, 145-155.
116. Shinohara, H.; Morita, S.; Kawai, M.; Miyamoto, A.; Sonoda, T.; Pastan, I.; Tanigawa, N. Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin. J. Surg. Res. 2002, 102, 169-177.